Mild cognitive impairment–amnestic type (MCI-AT) is mild, repeated memory loss. It lies between the normal memory loss of aging and the more serious conditions of dementia and Alzheimer’s disease (AD). MCI-AT only involves problems with memory. Dementia and Alzheimer's involve loss of other cognitive abilities, such as:
People with MCI-AT who are over age 65 have a higher chance of developing dementia and Alzheimer's. However, many people with MCI-AT never develop these disorders. Some even return to normal.
Some Areas of the Brain Affected by Dementia and Alzheimer's Disease
© 2009 Nucleus Medical Media, Inc.
These risk factors increase your chance of developing MCI-AT. Tell your doctor if you have any of these risk factors:
Research also suggests that these may be risk factors for MCI-AT:
The main symptom is frequent, ongoing memory loss beyond what is normally expected for one’s age. That means having more than small lapses of memory. If you have MCI-AT, you may:
The doctor will ask about your symptoms and medical history. She will also:
The doctor may also talk with family members and caregivers. If you have this condition, you should have your cognitive abilities tested regularly.
Treatment is focused:
Researchers are currently studying the effects that several medicines may have on slowing cognitive decline. Examples include donepezil, vitamin E, tacrine, among other medicines.
The following are being studied as ways to reduce the risk of cognitive decline:
American Psychiatric Association
http://www.psych.org/
National Institute on Aging
http://www.nia.nih.gov/
Alzheimer Association of Canada
http://www.alzheimer.ca/
Seniors Canada On-line
http://www.seniors.gc.ca/
Alzheimer’s disease education and referral center. Connections: News from the ADEAR Center 1999;8(2).
Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev. 2006;3:CD006104.
DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginko biloba for prevention of dementia: a randomized controlled trila. JAMA. 2008;300:2306-2308.
Feldman HH, Jacova C. Mild cognitive impairment. Am J Geriatr Psychiatry. 2005;13:645-655.
Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet . 2006;367:1262-1270.
Institute for the Study of Aging and International Longevity Center–USA (March 2001). Achieving and Maintaining Cognitive Vitality With Aging: A Workshop Report . New York, NY.
National Institute on Aging. 2001-2002 Progress Report on Alzheimer’s Disease . July 2003.
Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27. Available at: http://www.medscape.comn/viewarticle/553257 . Accessed March 23, 2007.
Petersen RC, Roberts RO, Knopmann DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447-1455.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology . 1999;56:303-308.
Last reviewed January 2010 by Rimas Lukas, MD
Last Updated: 1/21/2010
Copyright © 2010 EBSCO Publishing All rights reserved.
Sponsored by iHerb.Com
Positively the best overall value for natural products!